Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

Page 1 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=1' data-page='1' class='cut-thumb lazyload' alt='Page 1: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/1.jpg' width='140' height='200' />

Page 2 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=2' data-page='2' class='cut-thumb lazyload' alt='Page 2: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/2.jpg' width='140' height='200' />

Page 3 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=3' data-page='3' class='cut-thumb lazyload' alt='Page 3: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/3.jpg' width='140' height='200' />

Page 4 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=4' data-page='4' class='cut-thumb lazyload' alt='Page 4: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/4.jpg' width='140' height='200' />

Page 5 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=5' data-page='5' class='cut-thumb lazyload' alt='Page 5: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/5.jpg' width='140' height='200' />

Page 6 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=6' data-page='6' class='cut-thumb lazyload' alt='Page 6: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/6.jpg' width='140' height='200' />

Page 7 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=7' data-page='7' class='cut-thumb lazyload' alt='Page 7: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/7.jpg' width='140' height='200' />

Page 8 <img data-url='document/newsletter-issue-1-july-2016-lsrnwacuk-712016-vegf-therapy-for-triple-negative.html?page=8' data-page='8' class='cut-thumb lazyload' alt='Page 8: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader036.cupdf.com/reader036/viewer/2022080723/5f7bec55200476558e30fad7/html5/thumbnails/8.jpg' width='140' height='200' />

Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016 · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

Documents